Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bicycle Therapeutics ( (BCYC) ) has provided an announcement.
On September 8, 2025, Bicycle Therapeutics announced the expansion of its Board of Directors from eight to ten members, appointing Roger Dansey, M.D., and Hervé Hoppenot as new directors. Both appointees bring extensive expertise in oncology research, drug development, and commercialization, which is expected to enhance the company’s strategic initiatives in developing next-generation targeted therapies. The appointments are seen as a strategic move to strengthen the company’s leadership as it progresses with its pipeline and anticipates upcoming milestones.
The most recent analyst rating on (BCYC) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.
Spark’s Take on BCYC Stock
According to Spark, TipRanks’ AI Analyst, BCYC is a Neutral.
Bicycle Therapeutics faces significant financial challenges with declining revenues and persistent losses, which weigh heavily on its overall score. The technical analysis suggests a bearish trend, further impacting the score. While the valuation indicates potential upside, the lack of earnings call data and the absence of a dividend yield limit the stock’s appeal. Strong shareholder support at the recent annual meeting is a positive sign but does not significantly alter the overall assessment.
To see Spark’s full report on BCYC stock, click here.
More about Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic short peptides designed to target diseases underserved by existing therapeutics, with a focus on oncology. The company is headquartered in Cambridge, UK, and has key functions in Cambridge, Massachusetts.
Average Trading Volume: 275,861
Technical Sentiment Signal: Sell
Current Market Cap: $495.9M
See more data about BCYC stock on TipRanks’ Stock Analysis page.